About Genocea

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines and exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea is exploring strategic alternatives for GEN-003, its Phase 3-ready immunotherapy candidate for the treatment of genital herpes.

adjusted-apc-t-cell-image2

Stock Quote

NASDAQ GNCA
$1.07
+ 0.03 (+2.89%)


0.56M

Volume

$1.08

Day High

$1.01

Day Low

Dec 15, 2017 ET on 4:00 PM Delayed at least 20 minutes.

Stock Chart